Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.
"'The market environment will likely become a bit more difficult in the coming week, as supply will jump to its highest level ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback